# Unraveling small non-coding RNAs with a significant post-transcriptional impact on breast cancer cell signaling, using a combinational sequencing approach

**Authors:** Katerina Katsaraki, Vaia K. Stafyla, Diamantis C. Sideris, Andreas Scorilas, Christos K. Kontos

PMC · DOI: 10.1007/s10142-026-01856-6 · Functional & Integrative Genomics · 2026-03-23

## TL;DR

This study identifies small non-coding RNAs that significantly influence breast cancer cell signaling through a sequencing approach, revealing potential regulatory mechanisms.

## Contribution

A novel combinational sequencing approach uncovers post-transcriptional regulatory small non-coding RNAs impacting breast cancer signaling.

## Key findings

- miR-489-3p, miR-876-3p, and miR-1827 show consistent expression changes across breast cancer cell lines.
- Specific tRNA-derived fragments and piRNAs are induced, suggesting roles in breast cancer biology.
- miR-22-5p interacts with the PI3K/AKT pathway and inhibits cancer cell proliferation and migration.

## Abstract

Breast cancer (BrCa) is a predominant type of cancer with high mortality rates. The deregulation of cell signaling pathways is a hallmark of BrCa pathogenesis and disease progression. Aiming to explore novel post-transcriptional regulatory mechanisms influencing BrCa cell signaling, a combinational sequencing approach was employed by integrating small RNA sequencing with poly(A)-RNA sequencing, following the alteration of cell signaling using proteasome inhibitors. Pursuing a broad analysis of BrCa gene expression, cell lines deriving from the major molecular subtypes were incorporated. Gene expression changes were detected after treatment with both inhibitors, with the strongest overlap in the Luminal B and TNBC cells. The altered small non-coding RNA profiles suggested broad regulatory effects on genes central to BrCa biology and cell signaling. Interestingly, miR-489-3p and miR-876-3p were consistently downregulated and miR-1827 upregulated among the studied conditions, while other miRNAs were characterized with cell-line specific alterations. Several piRNAs, including piR-36,318, piR-39,245, and piR-36,036, were markedly induced. Specific tRNA-derived RNA fragments such as 5’-tRF-TRN-GTT11, 3’-tRF-TRQ-CTG3, i-tRF-TRQ-CTG3(1), and 5’-tRF-TRV-CAC14 stood out with a potential contribution to regulatory axes shaping BrCa biology. Furthermore, an upregulation of miR-22-5p/3p and a relevant downregulation of specific targets was observed in two TNBC cell lines of metastatic origin. The luciferase activity assay revealed a direct interaction of miR-22-5p with the components of the PI3K/AKT pathway, INSR, ITGB8, and PI3KR1. Lastly, the overexpression of mir-22 inhibited cell proliferation and migration. In conclusion, our combinational sequencing approach unraveled several small non-coding RNAs with a significant post-transcriptional impact on BrCa cell signaling.

The online version contains supplementary material available at 10.1007/s10142-026-01856-6.

## Linked entities

- **Genes:** INSR (insulin receptor) [NCBI Gene 3643], ITGB8 (integrin subunit beta 8) [NCBI Gene 3696]
- **Diseases:** breast cancer (MONDO:0004989)

## Full-text entities

- **Genes:** NR4A1 (nuclear receptor subfamily 4 group A member 1) [NCBI Gene 3164] {aka GFRP1, HMR, N10, NAK-1, NGFIB, NP10}, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}, RAD51D (RAD51 paralog D) [NCBI Gene 5892] {aka BROVCA4, R51H3, RAD51L3, TRAD}, STK11 (serine/threonine kinase 11) [NCBI Gene 6794] {aka LKB1, PJS, hLKB1}, RAD51C (RAD51 paralog C) [NCBI Gene 5889] {aka BROVCA3, FANCO, R51H3, RAD51L2}, CD14 (CD14 molecule) [NCBI Gene 929], TWIST1 (twist family bHLH transcription factor 1) [NCBI Gene 7291] {aka ACS3, BPES2, BPES3, CRS, CRS1, CSO}, PIK3R1 (phosphoinositide-3-kinase regulatory subunit 1) [NCBI Gene 5295] {aka AGM7, GRB1, IMD36, p85, p85-ALPHA, p85alpha}, FLNC (filamin C) [NCBI Gene 2318] {aka ABP-280, ABP280A, ABPA, ABPL, ARVC15, CMD1PP}, TERF1 (telomeric repeat binding factor 1) [NCBI Gene 7013] {aka PIN2, TRBF1, TRF, TRF1, hTRF1-AS, t-TRF1}, HSPA1B (heat shock protein family A (Hsp70) member 1B) [NCBI Gene 3304] {aka HSP70-1, HSP70-1B, HSP70-2, HSP70.1, HSP70.2, HSP72}, PRLR (prolactin receptor) [NCBI Gene 5618] {aka HPRL, MFAB, RI-PRLR, hPRLrI}, MAP3K12 (mitogen-activated protein kinase kinase kinase 12) [NCBI Gene 7786] {aka DLK, HP09298, MEKK12, MUK, ZPK, ZPKP1}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, PTGS2 (prostaglandin-endoperoxide synthase 2) [NCBI Gene 5743] {aka COX-2, COX2, GRIPGHS, PGG/HS, PGHS-2, PHS-2}, FGFR3 (fibroblast growth factor receptor 3) [NCBI Gene 2261] {aka ACH, CD333, CEK2, HSFGFR3EX, JTK4}, MDM2 (MDM2 proto-oncogene) [NCBI Gene 4193] {aka ACTFS, HDMX, LSKB, hdm2}, PALB2 (partner and localizer of BRCA2) [NCBI Gene 79728] {aka BROVCA5, FANCN, PNCA3}, MIR1827 (microRNA 1827) [NCBI Gene 100302217] {aka MIRN1827, hsa-mir-1827}, MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609] {aka MRTL, MYCC, bHLHe39, c-Myc}, EFNA5 (ephrin A5) [NCBI Gene 1946] {aka AF1, EFL5, EPLG7, GLC1M, LERK7, RAGS}, DUSP3 (dual specificity phosphatase 3) [NCBI Gene 1845] {aka VHR}, BDNF (brain derived neurotrophic factor) [NCBI Gene 627] {aka ANON2, BULN2}, ATM (ATM serine/threonine kinase) [NCBI Gene 472] {aka AT1, ATA, ATC, ATD, ATDC, ATE}, ZEB1 (zinc finger E-box binding homeobox 1) [NCBI Gene 6935] {aka AREB6, BZP, DELTAEF1, FECD6, NIL2A, PPCD3}, RAP1B (RAP1B, member of RAS oncogene family) [NCBI Gene 5908] {aka K-REV, RAL1B, THC11}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, RBL2 (RB transcriptional corepressor like 2) [NCBI Gene 5934] {aka BRUWAG, P130, Rb2}, CDK6 (cyclin dependent kinase 6) [NCBI Gene 1021] {aka MCPH12, PLSTIRE}, IL6R (interleukin 6 receptor) [NCBI Gene 3570] {aka CD126, HIES5, IL-1Ra, IL-6R, IL-6R-1, IL-6RA}, MYB (MYB proto-oncogene, transcription factor) [NCBI Gene 4602] {aka Cmyb, c-myb, c-myb_CDS, efg}, CCND1 (cyclin D1) [NCBI Gene 595] {aka BCL1, D11S287E, PRAD1, U21B31}, SNORD44 (small nucleolar RNA, C/D box 44) [NCBI Gene 26806] {aka RNU44, U44}, TRN-GTT2-7 (tRNA-Asn (anticodon GTT) 2-7) [NCBI Gene 7214] {aka TRN, TRN1}, MEF2C (myocyte enhancer factor 2C) [NCBI Gene 4208] {aka C5DELq14.3, DEL5q14.3, NEDHSIL}, CTNNB1 (catenin beta 1) [NCBI Gene 1499] {aka CTNNB, EVR7, MRD19, NEDSDV, armadillo}, LAMC1 (laminin subunit gamma 1) [NCBI Gene 3915] {aka LAMB2}, LY96 (lymphocyte antigen 96) [NCBI Gene 23643] {aka ESOP-1, MD-2, MD2, ly-96}, CDKN1A (cyclin dependent kinase inhibitor 1A) [NCBI Gene 1026] {aka CAP20, CDKN1, CIP1, MDA-6, P21, SDI1}, EGF (epidermal growth factor) [NCBI Gene 1950] {aka HOMG4, URG}, MRAS (muscle RAS oncogene homolog) [NCBI Gene 22808] {aka M-RAs, NS11, R-RAS3, RRAS3}, CXCL12 (C-X-C motif chemokine ligand 12) [NCBI Gene 6387] {aka IRH, PBSF, SCYB12, SDF1, TLSF, TPAR1}, MIR320E (microRNA 320e) [NCBI Gene 100422913] {aka mir-320e}, PTEN (phosphatase and tensin homolog) [NCBI Gene 5728] {aka 10q23del, BZS, CWS1, DEC, GLM2, MHAM}, CDH1 (cadherin 1) [NCBI Gene 999] {aka Arc-1, BCDS1, CD324, CDHE, ECAD, LCAM}, MIR223 (microRNA 223) [NCBI Gene 407008] {aka MIRN223, miRNA223, mir-223}, PPP2R2C (protein phosphatase 2 regulatory subunit Bgamma) [NCBI Gene 5522] {aka B55-GAMMA, B55gamma, IMYPNO, IMYPNO1, PR52, PR55G}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, NTRK1 (neurotrophic receptor tyrosine kinase 1) [NCBI Gene 4914] {aka MTC, TRK, TRK1, TRKA, Trk-A, p140-TrkA}, CACNA2D2 (calcium voltage-gated channel auxiliary subunit alpha2delta 2) [NCBI Gene 9254] {aka CACNA2D, CASVDD}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, CXCL2 (C-X-C motif chemokine ligand 2) [NCBI Gene 2920] {aka CINC-2a, GRO2, GROb, MGSA-b, MIP-2a, MIP2}, ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}, HSPA6 (heat shock protein family A (Hsp70) member 6) [NCBI Gene 3310] {aka HSP70B'}, CHEK2 (checkpoint kinase 2) [NCBI Gene 11200] {aka CDS1, CHK2, HuCds1, LFS2, PP1425, RAD53}, RB1 (RB transcriptional corepressor 1) [NCBI Gene 5925] {aka OSRC, PPP1R130, RB, p105-Rb, p110-RB1, pRb}, TGFBR1 (transforming growth factor beta receptor 1) [NCBI Gene 7046] {aka AAT5, ACVRLK4, ALK-5, ALK5, ESS1, LDS1}, CASP3 (caspase 3) [NCBI Gene 836] {aka CPP32, CPP32B, SCA-1}, INSR (insulin receptor) [NCBI Gene 3643] {aka CD220, HHF5}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}
- **Diseases:** Cancer (MESH:D009369), inflammation (MESH:D007249), carcinogenic agents (MESH:D011230), ovarian cancer (MESH:D010051), BrCa (MESH:D001943), obesity (MESH:D009765), carcinogenesis (MESH:D063646), lung metastasis (MESH:D009362), Luminal B (MESH:D006509), breast carcinogenesis (MESH:D061325)
- **Chemicals:** bortezomib (MESH:D000069286), CO2 (MESH:D002245), Sulforhodamine B (MESH:C022027), CTC12 (-), Poly(A) (MESH:D011061), agarose (MESH:D012685), doxorubicin (MESH:D004317), carfilzomib (MESH:C524865), ampicillin (MESH:D000667), alcohol (MESH:D000438)
- **Species:** Escherichia coli (E. coli, species) [taxon 562], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** MCF-7 — Homo sapiens (Human), Invasive breast carcinoma of no special type, Cancer cell line (CVCL_0031), DH5a — Drosophila hydei (Fruit fly), Spontaneously immortalized cell line (CVCL_Z531), Neo — Mus musculus (Mouse), Mouse melanoma, Cancer cell line (CVCL_J816), BT-20 — Homo sapiens (Human), Invasive breast carcinoma of no special type, Cancer cell line (CVCL_0178), MDA-MB-231 — Homo sapiens (Human), Breast adenocarcinoma, Cancer cell line (CVCL_0062), S2 — Drosophila melanogaster (Fruit fly), Spontaneously immortalized cell line (CVCL_Z232), SK-BR-3 — Homo sapiens (Human), Breast adenocarcinoma, Cancer cell line (CVCL_0033), MDA-MB-468 — Homo sapiens (Human), Breast adenocarcinoma, Cancer cell line (CVCL_0419), Luminal B — Mus musculus (Mouse), Carcinoma of the mouse prostate gland, Cancer cell line (CVCL_AV68), BT-474 — Homo sapiens (Human), Invasive breast carcinoma of no special type, Cancer cell line (CVCL_0179)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13006467/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13006467/full.md

## References

15 references — full list in the complete paper: https://tomesphere.com/paper/PMC13006467/full.md

---
Source: https://tomesphere.com/paper/PMC13006467